SCHEMBL22833738

SCHEMBL22833738

Cc1ccc(C(N)=O)cc1C#Cc1cccnc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.61
KIT P10721 4/20 0.52
ABL1 P00519 1/20 0.47
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
SARM1 Q6SZW1 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
SIRT6 Q8N6T7 1/20 0.46
SIRT1 Q96EB6 1/20 0.46
SIRT3 Q9NTG7 1/20 0.46
SIRT5 Q9NXA8 1/20 0.46
SIRT4 Q9Y6E7 1/20 0.46
MKNK1 Q9BUB5 4/20 0.45
MKNK2 Q9HBH9 4/20 0.45
CYP2A6 P11509 1/20 0.44
GRM5 P41594 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
DDR1 Q08345 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063968 0.88 CSF1R (0.62) CSF1RKITABL1MKNK1MKNK2
SCHEMBL11297061 0.86 CSF1R (0.67) CSF1RKITABL1DDR1
SCHEMBL22833769 0.85 CSF1R (0.68) CSF1RKITABL1GRM5PTGDR2
SCHEMBL22854604 0.85 CSF1R (0.68) CSF1RKITABL1MKNK1MKNK2
SCHEMBL29934174 0.83 CSF1R (0.43) CSF1RKITABL1GRM5DDR1
SCHEMBL31359379 0.82 CSF1R (0.44) CSF1RKITMKNK1MKNK2DDR1
SCHEMBL13765874 0.81 CSF1R (0.76) CSF1RKITABL1GRM5DDR1
SCHEMBL29506350 0.80 F7 (0.59) F7F3SARM1SIRT2SIRT6
SCHEMBL29934088 0.80 MKNK1 (0.56) CSF1RKITMKNK1MKNK2GRM5
SCHEMBL13765780 0.78 CSF1R (0.71) CSF1RKITABL1DDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119923398-A Cyclic compounds and methods of use thereof 薛定谔公司 2025-05-02 CN disclosed
US-20230014226-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2023-01-19 US disclosed
US-20230014226-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2023-01-19 US disclosed
EP-3986559-A1 NEW COMPOUNDS AND METHODS BenevolentAI Bio Limited (GB) 2022-04-27 EP disclosed
CN-114340734-A Novel compounds and methods 博善人工智能生物科技有限公司 2022-04-12 CN disclosed
WO-2020260871-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2020-12-30 WO disclosed
WO-2020260871-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014226-A1 NEW COMPOUNDS AND METHODS ABL2, ABL1, ALK CSF1R 4175/4885KIT 457/4885ABL1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.